Eva Walde strengthens Senzime’s Board of Directors

Report this content

Press release: Uppsala, October 19, 2020. Senzime announces that Eva Walde is appointed new acting Board Member to be elected at the next shareholder’s meeting.


Eva has a Master's degree in economics from the Gothenburg School of Economics and over 20 years of experience in leading roles in companies such as Johnson & Johnson, Pfizer and Thermo Fisher. Eva is currently a Board member of Sedana Medical AB (publ.), a volatile anaesthetic delivery company, and the VP of Marketing at Olink AB."We are very pleased to appoint such an experienced person as Eva Walde to Senzime's Board. Eva has solid background in international sales and marketing of medical technology and will be a great asset for Senzime in the commercial phase we are in now,” says Philip Siberg, Chairman of the Board of Senzime.

The appointment of a new Board member has taken place through an external recruitment process on behalf of the Nomination Committee of Senzime, consisting of Philip Siberg, Adam Dahlberg, Lennart Kalén and Sorin J. Brull.

For further information, please contact:

Philip Siberg, Chairman of the Board

Tel: +46 70 790 67 34

Pia Renaudin, CEO          

Phone: +46 70-813 34 17, e-post: pia.renaudin@senzime.com


About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se,  is Certified Adviser for Senzime. www.senzime.com